RemeGen Co

RemeGen Co Market capitalization

The The market capitalization of RemeGen Co (9995.HK) as of Nov 5, 2026 is 27.32 B CNY. In the previous year, The market capitalization was 27.32 B CNY — a change of 0.00% (lower).

Market capitalization

27.32 BCNY

YoY

0.00%

Last updated:

In 2025, RemeGen Co's market cap stood at 27.32 B CNY, a 0.00% increase from the 27.32 B CNY market cap in the previous year.

The RemeGen Co Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2018
27.32 B CNY
Jan 1, 2019
27.32 B CNY
Jan 1, 2020
27.32 B CNY
Jan 1, 2021
27.32 B CNY
Jan 1, 2022
27.32 B CNY
Jan 1, 2023
27.32 B CNY
Jan 1, 2024
27.32 B CNY
Jan 1, 2025
27.32 B CNY
The RemeGen Co Market capitalization history
YEARMarket capitalizationYoY
27.32 BCNY0.00%
27.32 BCNY0.00%
27.32 BCNY0.00%
27.32 BCNY0.00%
27.32 BCNY0.00%
27.32 BCNY0.00%
27.32 BCNY0.00%
27.32 BCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd is a Chinese biotechnology company based in Yantai. The company was founded in 2008 by Dr. Li Zhu, who also developed the company's main product. RemeGen's goal is to develop innovative therapies for the treatment of cancer and autoimmune diseases. The company's business model involves researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. RemeGen works closely with leading researchers from around the world and conducts clinical trials to assess the safety and efficacy of its products. The company has various divisions focused on developing drugs for different diseases, including oncology, autoimmune diseases, and dermatology. RemeGen's flagship product is the antibody FGFR4, which is a new therapeutic agent for treating liver cancer. FGFR4 is one of the most highly expressed genes in liver cancer cells and plays a crucial role in tumor progression. The antibody inhibits the activity of FGFR4, thereby preventing the growth of liver cancer cells. Clinical studies have shown FGFR4 to be a promising treatment option for liver cancer, with positive results. In addition to FGFR4, RemeGen has other promising products in its development pipeline, including the antibody RC48, which is used in the treatment of advanced or metastatic lung cancer. RC48 targets the Epidermal Growth Factor Receptor (EGFR), a protein that is highly upregulated in many types of cancer and promotes the growth of cancer cells. Clinical studies have shown RC48 to be a promising treatment option for lung cancer, reaching Phase III. Overall, RemeGen Co Ltd has a promising approach to developing innovative drugs that have the potential to change the standard of care in oncology, autoimmune diseases, and dermatology. Through close collaboration with leading researchers and clinical trials, the company is well-positioned to further develop its pipeline and improve medical care for patients in China and worldwide. Answer: RemeGen Co Ltd is a Chinese biotechnology company focused on developing innovative therapies for the treatment of cancer and autoimmune diseases. It has a business model of researching, developing, and bringing to market novel drugs that offer better efficacy and safety than existing treatment options. The company's divisions focus on oncology, autoimmune diseases, and dermatology. Its flagship product is the antibody FGFR4, which is used for treating liver cancer. RemeGen also has other promising products, such as the antibody RC48 for advanced lung cancer. The company's approach has the potential to change the standard of care in these medical fields. RemeGen Co is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring RemeGen Co's Market Capitalization

RemeGen Co's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of RemeGen Co's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

RemeGen Co's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in RemeGen Co’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about RemeGen Co stock

The market capitalization of RemeGen Co is 27.32 B CNY in 2025.

The market capitalization of RemeGen Co changed from 27.32 B CNY to 27.32 B CNY, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's CNY, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' CNY varies by industry and company stage. On Eulerpool, you can compare The market capitalization's RemeGen Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — RemeGen Co

All Key Metrics — RemeGen Co